Remission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter study

Página do item simplificado
dc.citation.issue5
dc.citation.volume40
dc.contributor.authorCasagrande, A. [UNIFESP]
dc.contributor.authorBronstein, M. D.
dc.contributor.authorJallad, R. S.
dc.contributor.authorMota, J. I.
dc.contributor.authorTabet, A.
dc.contributor.authorAbucham, J. [UNIFESP]
dc.coverageNew York
dc.date.accessioned2020-07-17T14:02:13Z
dc.date.available2020-07-17T14:02:13Z
dc.date.issued2017
dc.description.abstractPurpose Remission of acromegaly has been reported after somatostatin analogs withdrawal, but not after withdrawal of combination therapy with cabergoline, and only in case reports of patients controlled by cabergoline alone. Methods To establish the remission rates (normal IGF-1 for age/sex: IGF-1 <= 1.00 xULN) after withdrawal of combined treatment with octreotide LAR and cabergoline and of cabergoline alone, we prospectively studied 16 patients with acromegaly controlled by those treatments in the preceding 2 years as part of a larger study on remission of acromegaly after withdrawal of different medical treatments. Results Among 97 patients with controlled acromegaly included in the entire study, only 16 patients had been on combination therapy (n = 12) or cabergoline alone (n = 4). At 8 weeks after treatment withdrawal, three patients (19%) were in remission (short-term remission). At 60 weeks (long-term remission), IGF-1 levels were still in the normal range in two patients (12.5%) and remained normal up to 108 weeks after treatment withdrawal (last visit). One patient had been treated with cabergoline alone and another one with combination of octreotide and cabergoline before treatment withdrawal. Conclusion Remission of acromegaly after treatment withdrawal seems to be uncommon in patients controlled by cabergoline, either as monotherapy or in combination with octreotide. In the future, larger studies and/or meta-analysis will be necessary to accurately establish the remission rates of acromegaly after withdrawal of cabergoline with or without somatostatin analogs.en
dc.description.affiliationUniv Fed Sao Paulo, Div Endocrinol & Metab, Neuroendocrine Unit, Rua Botucatu 806, BR-04023062 Sao Paulo, SP, Brazil
dc.description.affiliationUniv Sao Paulo, Hosp Clin, Div Endocrinol & Metab, Neuroendocrine Unit, Sao Paulo, Brazil
dc.description.affiliationGen Hosp Fortaleza, Div Endocrinol, Fortaleza, Ceara, Brazil
dc.description.affiliationUniv Estado Rio De Janeiro, Div Endocrine, Dept Internal Med, Rio De Janeiro, Brazil
dc.description.affiliationUnifespUniv Fed Sao Paulo, Div Endocrinol & Metab, Neuroendocrine Unit, Rua Botucatu 806, BR-04023062 Sao Paulo, SP, Brazil
dc.description.sourceWeb of Science
dc.description.sponsorshipCoordenacao de Aperfeicoamento de Pessoal de Nivel Superior (BR)
dc.description.sponsorshipIDCAPES: 528/11
dc.format.extent523-528
dc.identifierhttp://dx.doi.org/10.1007/s40618-016-0595-5
dc.identifier.citationJournal Of Endocrinological Investigation. New York, v. 40, n. 5, p. 523-528, 2017.
dc.identifier.doi10.1007/s40618-016-0595-5
dc.identifier.issn1720-8386
dc.identifier.urihttps://repositorio.unifesp.br/handle/11600/54690
dc.identifier.wosWOS:000399306000009
dc.language.isoeng
dc.publisherSpringer
dc.relation.ispartofJournal Of Endocrinological Investigation
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAcromegalyen
dc.subjectCombination therapyen
dc.subjectRemissionen
dc.subjectOctreotideen
dc.subjectCabergolineen
dc.titleRemission of acromegaly after treatment withdrawal in patients controlled by cabergoline alone or in combination with octreotide: results from a multicenter studyen
dc.typeinfo:eu-repo/semantics/article
Arquivos
Coleções
EPM - Artigos